Mickaël Hiligsmann (M.J.C.)

Hiligsmann, M., Kong, S. H., Alokail, M., Kim, M.-Y., & Reginster, J.-Y. (2026). Evaluating the cost-effectiveness of artificial intelligence-enhanced osteoporosis screening in men and women using routine chest radiographs in South Korea. JBMR plus, 10(2), Article ziaf187. https://doi.org/10.1093/jbmrpl/ziaf187

Wiethoff, I., Witlox, W. J. A., Evers, S. M. A. A., Michels, M., & Hiligsmann, M. (2026). Model-Based Economic Evaluation of the First-in-Class Myosin Inhibitor Mavacamten Versus Care as Usual in Obstructive Hypertrophic Cardiomyopathy Patients from a Dutch Societal Perspective. Pharmacoeconomics, 44(2), 245-259. https://doi.org/10.1007/s40273-025-01564-2

Li, N., Rambod, B., Dukers-Muijrers, N., Chevalier, J. M., Steijvers, L., Kojan, L., Wijnen, S., Crutzen, R., Jahn, B., Siebert, U., Stellbrink, L., Van Daalen, F., Kretzschmar, M., & Hiligsmann, M. (2026). General population preferences for health-related protective behaviors during infectious disease emergencies: a systematic review of conjoint-analysis studies. Social Science & Medicine, 388, Article 118721. https://doi.org/10.1016/j.socscimed.2025.118721

Chandran, M., Reginster, J.-Y., Kim, M.-Y., & Hiligsmann, M. (2026). Clinical and economic impact of deep learning-enhanced opportunistic osteoporosis screening using chest radiographs with and without the osteoporosis self-assessment tool for Asians (OSTA). Osteoporosis International. Advance online publication. https://doi.org/10.1007/s00198-026-07858-1

Iskandar, K., Roques, C., Salameh, P., Rizk, R., Daham, J., Hiligsmann, M., Karam, R., & Molinier, L. (2026). Economics perspectives on understanding antimicrobial use and resistance: a scoping review from theory to practice. Expert Review of Pharmacoeconomics & Outcomes Research, 26(1), 33-52. https://doi.org/10.1080/14737167.2025.2591291

Heinz, K. C., Beaudart, C., De Greef, A., Vanhooteghem, O., Gostynski, A., & Hiligsmann, M. (2026). Patients' preferences for atopic dermatitis treatments in Europe: a discrete choice experiment. Expert Review of Pharmacoeconomics & Outcomes Research, 26(1), 131-138. https://doi.org/10.1080/14737167.2025.2594633

Li, N., Majoie, M., Evers, S., Rijkers, K., Gubler, F., Rouhl, R., Lazeron, R., Klarenbeek, P., Laskier-Owens, V., & Hiligsmann, M. (2025). Budget impact analysis of cenobamate for epilepsy patients with drug-resistant focal onset seizures in the Netherlands. Journal of Medical Economics, 28(1), 114-123. https://doi.org/10.1080/13696998.2024.2443338

Veronese, N., Barratt, J., Coemans, E., Dayananda, P., Del Riccio, M., Fulop, T., Gabutti, G., Gravenstein, S., Hiligsmann, M., Hummers, E., Kassianos, G., Macchia, F., Manzoni, P., Martin, F. C., Michel, J.-P., Morandi, A., Ory, J., Pattyn, J., Peetermans, E., ... Maggi, S. (2025). Infectious diseases, infection control, vaccines and long-term care: an European interdisciplinary Council on ageing consensus document. Aging Clinical and Experimental Research, 38(1), Article 10. https://doi.org/10.1007/s40520-025-03271-6

Vu, M. N., Westra, T. A., & Hiligsmann, M. (2025). A qualitative study on vaccination program accessibility for the elderly and medical risk groups in the south of the Netherlands. Vaccine: X, 27, Article 100713. https://doi.org/10.1016/j.jvacx.2025.100713

Maas, L., Contreras-Meca, C., Ghezzo, S., Belmans, F., Corsi, A., Cant, J., Vos, W., Bobowicz, M., Rygusik, M., Laski, D. K., Annemans, L., Hiligsmann, M., Lambin, P., & Woodruff, H. (2025). Cost-effectiveness analysis of artificial intelligence (AI) in earlier detection of liver lesions in cirrhotic patients at risk of hepatocellular carcinoma in Italy. Journal of Medical Economics, 28(1), 1023-1036. https://doi.org/10.1080/13696998.2025.2525006